In conclusion, Notch3 inhibition might protect podocytes and decrease the PEC activation, suggesting a novel therapeutic strategy for FSGS and rapidly progressive glomerulonephritis (RPGN). This evidence concerns the gene NOTCH3 and focal segmental glomerulosclerosis.